Gilead Moves Deeper into Oncology with $21 Billion Acquisition of Immunomedics

Gilead Sciences announced it has acquired Immunomedics, a developer of antibody-drug conjugate (ADC) technology used to treat cancers. Immunomedics gained attention with the success of Trodelvy, the first FDA-approved anti-TROP agent used against third-line metastatic triple-negative breast cancer. The drug is currently being studied for its potential to treat other forms of cancer.  

READ THE STORY at BioSpace »